TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18653310
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive behavior therapy (CBT)
Study: 22001151
Drug: Topical ciclosporin
Normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical ciclosporin A (CsA) 2%
Study: 7871449
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ciprofloxacin
Study: 3764628
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ciprofloxacin
Study: 27722222
Drug: Immediate-delayed implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-delayed implants (6 weeks)
Study: 27722222
Drug: Delayed implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implants (4 months)
Study: 18503141
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tadalafil + 5 mg nitrendipine
Study: 12702127
Drug: Trizivir (abacavir-lamivudine-zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trizivir (abacavir-lamivudine-zidovudine combination tablet) administered twice daily
Study: 12702127
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment (two nucleoside reverse transcriptase inhibitors plus a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor or three nucleoside reverse transcriptase inhibitors)
Study: 12702127
Drug: Trizivir (abacavir-lamivudine-zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trizivir (abacavir-lamivudine-zidovudine combination tablet)
Study: 10752915
Drug: Flunisolide administered
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide administered via AeroChamber, 750 microg (3 puffs), twice daily
Study: 10752915
Drug: Budesonide administered
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide administered via Turbuhaler, 600 microg (3 puffs), twice daily
Study: 9373479
Drug: Topical levobunolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levobunolol HCl 0.5% (LEV)
Study: 9373479
Drug: Topical levobunolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levobunolol HCl 0.5% (LEV) vs Artificial tears (TEAR)
Study: 27943153
Drug: Sorafenib 200
Normalized name: sorafenib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 200 mg BID days 1-28 plus Bevacizumab 2.5 mg/kg every other week (MTD)
Study: 27943153
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg BID (phase I)
Study: 27943153
Drug: Sorafenib 200
Normalized name: sorafenib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 200 mg BID plus Bevacizumab 2.5 mg/kg (phase II)
Study: 29798325
Drug: Yanhouqing buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yanhouqing buccal tablets (high dose)
Study: 29798325
Drug: Yanhouqing buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yanhouqing buccal tablets (low dose)
Study: 29798325
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Yanhouqing buccal tablets and placebo)
Study: 24619016
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg (80 mg/day) administered twice daily (4 and 3 hours prior to each radiotherapy fraction)
Study: 24619016
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily (4 and 3 hours prior to each radiotherapy fraction)
Study: 19741581
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/day, group A, N. 22)
Study: 14633533
Drug: Esmolol 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 50 mg and nicardipine 1 mg, followed by an esmolol infusion 5 microg x kg(‐1) x min(‐1)
Study: 14633533
Drug: Esmolol 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 50 mg, followed by an esmolol infusion 5 microg x kg(‐1) x min(‐1)
Study: 14633533
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion as an adjunct to desflurane
Study: 14633533
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 5 mL and 1 mL, followed by a saline infusion at a rate of 0.005 mL x kg(‐1) x min(‐1)
Study: 10540300
Drug: Regimen I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen I: 300 mg dihydroartemisinin + 750 mg mefloquine concurrently
Study: 10540300
Drug: Regimen II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen II: 300 mg dihydroartemisinin + 750 mg mefloquine 24 h later
Study: 10540300
Drug: Regimen III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen III: 300 mg dihydroartemisinin + 750 mg mefloquine at 24 h and 500 mg at 30 h
Study: 10540300
Drug: Regimen IV:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen IV: 300 mg dihydroartemisinin + 750 mg mefloquine at 0 h and 500 mg at 24 h
Study: 10540300
Drug: High-dose mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose mefloquine regimens (III and IV)
Study: 10540300
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who vomited within the first hour of mefloquine administration
Study: 7037162
Drug: Cyclophosphamide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 600 mg/m2 IV plus DTIC 600 mg/m2 IV day 1 (CD)
Study: 7037162
Drug: Cyclophosphamide 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 400 mg/m2 IV, DTIC 400 mg/m2 IV, and piperazinedione 4 mg/m2 IV on day 1 (PCD)
Study: 7037162
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment programs (CD and PCD)
Study: 31665314
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg every 6 months in year 1
Study: 31665314
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg once-weekly in year 2
Study: 23812892
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted cognitive-behavioral therapy for adherence and depression with an alarmed pillbox
Study: 10443750
Drug: Insulin (0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.035 IU/kg i.v.)
Study: 8688258
Drug: Neostigmine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.05 mg kg‐1 and glycopyrronium 0.01 mg kg‐1
Study: 8688258
Drug: No neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neuromuscular blockers
Study: 6352035
Drug: Gentamicin-cefoxitin (G-C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin-cefoxitin (G-C)
Study: 18085139
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Lactein tablets, 1-2 tablets, 3 times daily for 4 weeks
Study: 9165134
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus 6 mg/m2 of cisplatin (CDPP)
Study: 9165134
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus 25 mg/m2 of carboplatin (CBDCA)
Study: 24335056
Drug: G allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: G allele of MTNR1B rs10830963
Study: 24334573
Drug: rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (10 mg per day)
Study: 24334573
Drug: simvastatin/ezetimibe (10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin/ezetimibe (10/10 mg per day)
Study: 16671429
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (S group)
Study: 16671429
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (C group)
Study: 8230497
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium citrate (30 to 60 mEq daily for 3 years)
Study: 3764522
Drug: Single-dose parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose parenteral therapy
Study: 3764522
Drug: Triple-dose parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-dose parenteral therapy
Study: 3764522
Drug: Parenteral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral and lavage therapy
Study: 3764522
Drug: Lavage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavage therapy alone
Study: 18948425
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole (200 mg twice daily)
Study: 14988448
Drug: Dairy protein
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy protein diet (DP, 2400 mg Ca/d)
Study: 14988448
Drug: Mixed protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed protein sources diet (MP, 500 mg Ca/d)
Study: 31492652
Drug: Ozanimod 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod 1.0 mg
Study: 26879276
Drug: Ozanimod 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod 0.5 mg
Study: 27418639
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) treatment
Study: 25552364
Drug: CEF (dose-intense
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF (dose-intense cyclophosphamide, epirubicin, and flurouracil)
Study: 25552364
Drug: EC/T (dose-dense,
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC/T (dose-dense, dose-intense epirubicin, cyclophosphamide, and paclitaxel)
Study: 21610239
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (60 mg/d for 14 days with a 5-day taper)
Study: 21610239
Drug: Intratympanic methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic methylprednisolone (4 doses over 14 days of 40 mg/mL injected into the middle ear)
Study: 19904567
Drug: PSE-enriched margarine
Normalized name: MARGARINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSE-enriched margarine (2.5 g/day of plant stanols)
Study: 16739847
Drug: Blood-letting therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-letting therapy combined with tapping Huatuo Jiaji (EX-B2) on the back by plum-blossom needle, once daily for 6 times (1 course)
Study: 16739847
Drug: Routine acupuncture
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine acupuncture at points of the four limbs, once daily for 12 times (1 course)
Study: 9612237
Drug: Sodium phenylbutyrate
Normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium phenylbutyrate (phi B) at a dose of 0.36 g.kg‐1.day‐1 for 24 hours
Study: 31192682
Drug: PUFA Ω‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA Ω‐3 (2.4 g/day; EPA 1.6 g and DHA 0.8 g)
Study: 26304969
Drug: 3-month diabetes
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month diabetes self-management education (DSME) program followed by 12 months of weekly group sessions and supplementary telephone support delivered by peer leaders
Study: 23100082
Drug: Ozone treatment
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone treatment via major autohemotherapy (10 sessions)
Study: 23100082
Drug: Betahistine (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (48 mg/day for 3 months)
Study: 18484559
Drug: Moderate insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate insulin infusion (0.8 microU/kg/min)
Study: 18484559
Drug: High insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High insulin infusion (1.6 microU/kg/min)
Study: 18484559
Drug: Hypoglycemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (blood glucose lowered to 2.5 mmol/l)
Study: 14662282
Drug: FDG PET-guided
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG PET-guided therapy
Study: 11451177
Drug: HBV vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccination (preS2/S, GenHevac B, Pasteur‐Mérieux), 20 microg, five intramuscular injections
Study: 11451177
Drug: HBV vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccination (S vaccine, Recombivax Merck & Co.), five intramuscular injections
Study: 11451177
Drug: HBV vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccination (any vaccine), five injections
Study: 11451177
Drug: HBV vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccination (any vaccine)
Study: 7799770
Drug: 20 g.l‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g.l‐1 glucose solution
Study: 7799770
Drug: 40 g.l‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g.l‐1 glucose solution
Study: 7799770
Drug: 60 g.l‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g.l‐1 glucose solution
Study: 29031889
Drug: Pressure garment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure garment therapy (PGT)
Study: 23180114
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg once daily until disease progression or unacceptable toxicity
Study: 25073663
Drug: peginterferon-β1a 125
Normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon-β1a 125 µg via single-use autoinjector
Study: 21983985
Drug: Dialysate with
Normalized name: Dialyvite 800 with Zinc Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate with low K (2 mmol/L), low Ca (1.25 mmol/L), high bicarbonate (34 mmol)
Study: 21983985
Drug: Dialysate with
Normalized name: Dialyvite 800 with Zinc Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate with high K (3 mmol/L), high Ca (1.75 mmol/L), bicarbonate (30 mmol)
Study: 19923061
Drug: Premarin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin (0.3 mg/day and 0.6 mg/day alternately, n=29)
Study: 19923061
Drug: Kuntai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuntai capsule (4 g/day, n=28)
Study: 15345733
Drug: 0.25 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/day micronized 17beta-estradiol (E2)
Study: 15345733
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day micronized 17beta-estradiol (E2)
Study: 15345733
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day micronized 17beta-estradiol (E2)
Study: 10209728
Drug: Oral brovincamine
Normalized name: vincamine
DrugBank: Vincamine (DB13374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral brovincamine (20 mg three times daily)
Study: 722768
Drug: Ratings administered
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ratings administered immediately before or after the final examination
Study: 19873916
Drug: Electroacupuncture (Baihui
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (Baihui (GV 20) and Taiyang (EXHN 5), once daily)
Study: 19873916
Drug: Modified Electric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Electric Convulsive Therapy (MECT, treatment once every 2 or 3 days for 14 to 21 days)
Study: 18214053
Drug: Ondansetron conventional
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron conventional tablet (OT) 8 mg twice daily for 3 days
Study: 18214053
Drug: Ondansetron orally
Normalized name: Ondansetron Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron orally disintegrating tablet (ODT) 8 mg twice daily for 3 days
Study: 15126539
Drug: Dutasteride 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 5.0 mg
Study: 11414666
Drug: N-acetylcysteine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (6 g daily for three days)
Study: 9215320
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg DHEA daily for 2 weeks
Study: 1917031
Drug: Cefaclor (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (250 mg t.i.d. for seven days)
Study: 1917031
Drug: Amoxycillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (250 mg t.i.d. for seven days)
Study: 7042501
Drug: Cefamandole prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole prophylactic therapy
Study: 26660491
Drug: 1.5% 3-butenyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% 3-butenyl 5-aminolevulinate gel (ALA-bu)
Study: 15801938
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg twice daily for 8 days
Study: 10233489
Drug: Hybrid laser
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid laser treatment (30 W KTP and 60 W Nd:YAG)
Study: 31739840
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium chewable tablets combined with inhaled budesonide
Study: 31739840
Drug: Single-drug group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug group (either montelukast sodium or budesonide)
Study: 22076751
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg/day for 14 days)
Study: 11169254
Drug: HLA-G*0105N allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA-G*0105N allele
Study: 15090794
Drug: HLA-G*010108 allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA-G*010108 allele
Study: 15090794
Drug: HLA-G*010108/010401 genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA-G*010108/010401 genotype
Study: 15090794
Drug: HLA-G*010101/010108 genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA-G*010101/010108 genotype
Study: 3154674
Drug: Nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 10 mg once a day
Study: 26240230
Drug: thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: thyroid hormone withdrawal (THW)
Study: 18082498
Drug: Class IC
Normalized name: Antiarrhythmics, class Ic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class IC antiarrhythmic drugs (AADs)
Study: 14572748
Drug: Strontium(89) Chloride
Normalized name: strontium chloride
DrugBank: Strontium chloride (DB13987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strontium(89) Chloride (150MBq, single intravenous injection)
Study: 19062012
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive alone
Study: 19062012
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive combined with a GnRH analog
Study: 11722711
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol propionate ointment (0.05%) applied three times a day
Study: 11722711
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate in an oral analgesic base (Orabase‐B) (1:1) applied two times a day
Study: 8989238
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (12.5 micrograms/kg per day)
Study: 8480572
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preprocedural heparin)
Study: 2953219
Drug: Nafazatrom 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafazatrom 800 mg four times daily for 1 week
Study: 2953219
Drug: Nafazatrom 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafazatrom 1600 mg four times daily for 1 week
Study: 2953219
Drug: Nafazatrom treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafazatrom treatment
Study: 29769450
Drug: HSPPC‐96 vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSPPC‐96 vaccination in combination with standard treatment after surgical resection
Study: 18391619
Drug: New prognostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New prognostic classification based on residual disease after neoadjuvant chemotherapy
Study: 14526714
Drug: CHM extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHM extract capsule (containing 18 herbs), given daily for 8 weeks
Study: 14526714
Drug: Placebo, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given daily for 8 weeks
Study: 14526714
Drug: CHM extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHM extract capsule
Study: 8879380
Drug: Oral ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ifosfamide (OSI) at a dose of 1 g/day for 14 days every 4 weeks
Study: 8879380
Drug: Intravenous ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ifosfamide (IVI) at a dose of 1.6 g/m2/day for 5 days every 4 weeks
Study: 8879380
Drug: Oral ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ifosfamide (OSI)
Study: 8879380
Drug: Intravenous ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ifosfamide (IVI)
Study: 1848054
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Enoxaparin), 30 mg subcutaneously twice daily for 14 days or until discharge.
Study: 1848054
Drug: Standard calcium
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard calcium heparin, 7500 units subcutaneously twice daily for 14 days or until discharge.
Study: 31022366
Drug: Combination instruments
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination instruments (hearing aids with a built-in sound generator)
Study: 29651778
Drug: Telephone follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone follow-up administered by specialist nurses